Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment
<p>Protein therapeutics play a significant role in treating many diseases. They, however, suffer from patient’s proteases degradation and antibody neutralization which lead to short plasma half-lives. One of the ways to overcome these pitfalls is the frequent injection of the drug albeit at th...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Published: |
2019
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1864513510847807488 |
|---|---|
| author | Alanod D. AlQahtani (18805930) |
| author2 | David O’Connor (108088) Alexander Domling (18805927) Sayed K. Goda (5146160) |
| author2_role | author author author |
| author_facet | Alanod D. AlQahtani (18805930) David O’Connor (108088) Alexander Domling (18805927) Sayed K. Goda (5146160) |
| author_role | author |
| dc.creator.none.fl_str_mv | Alanod D. AlQahtani (18805930) David O’Connor (108088) Alexander Domling (18805927) Sayed K. Goda (5146160) |
| dc.date.none.fl_str_mv | 2019-05-01T00:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1016/j.biopha.2019.108750 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Strategies_for_the_production_of_long-acting_therapeutics_and_efficient_drug_delivery_for_cancer_treatment/26015830 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Medical biotechnology Ophthalmology and optometry Pharmacology and pharmaceutical sciences PEGylations Human serum albumin Targeted cancer cells Drug delivery Half-life extension Protein immunogenicity |
| dc.title.none.fl_str_mv | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Protein therapeutics play a significant role in treating many diseases. They, however, suffer from patient’s proteases degradation and antibody neutralization which lead to short plasma half-lives. One of the ways to overcome these pitfalls is the frequent injection of the drug albeit at the cost of patient compliance which affects the quality of life of patients. There are several techniques available to extend the half-life of therapeutics. Two of the most common protocols are PEGylation and fusion with human serum albumin. These two techniques improve stability, reduce immunogenicity, and increase drug resistance to proteases. These factors lead to the reduction of injection frequency which increases patient compliance and improve quality of life. Both techniques have already been used in many FDA approved drugs. This review describes many technologies to produce long-acting drugs with the attention of PEGylation and the genetic fusion with human serum albumin. The report also discusses the latest modified therapeutics in the field and their application in cancer therapy. We compare the modification methods and discuss the pitfalls of these modified drugs.</p><h2>Other Information</h2> <p> Published in: Biomedicine & Pharmacotherapy<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.biopha.2019.108750" target="_blank">https://dx.doi.org/10.1016/j.biopha.2019.108750</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_212fd7846ce35d8e0a53b79e847e52e8 |
| identifier_str_mv | 10.1016/j.biopha.2019.108750 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/26015830 |
| publishDate | 2019 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatmentAlanod D. AlQahtani (18805930)David O’Connor (108088)Alexander Domling (18805927)Sayed K. Goda (5146160)Biomedical and clinical sciencesMedical biotechnologyOphthalmology and optometryPharmacology and pharmaceutical sciencesPEGylationsHuman serum albuminTargeted cancer cellsDrug deliveryHalf-life extensionProtein immunogenicity<p>Protein therapeutics play a significant role in treating many diseases. They, however, suffer from patient’s proteases degradation and antibody neutralization which lead to short plasma half-lives. One of the ways to overcome these pitfalls is the frequent injection of the drug albeit at the cost of patient compliance which affects the quality of life of patients. There are several techniques available to extend the half-life of therapeutics. Two of the most common protocols are PEGylation and fusion with human serum albumin. These two techniques improve stability, reduce immunogenicity, and increase drug resistance to proteases. These factors lead to the reduction of injection frequency which increases patient compliance and improve quality of life. Both techniques have already been used in many FDA approved drugs. This review describes many technologies to produce long-acting drugs with the attention of PEGylation and the genetic fusion with human serum albumin. The report also discusses the latest modified therapeutics in the field and their application in cancer therapy. We compare the modification methods and discuss the pitfalls of these modified drugs.</p><h2>Other Information</h2> <p> Published in: Biomedicine & Pharmacotherapy<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.biopha.2019.108750" target="_blank">https://dx.doi.org/10.1016/j.biopha.2019.108750</a></p>2019-05-01T00:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1016/j.biopha.2019.108750https://figshare.com/articles/journal_contribution/Strategies_for_the_production_of_long-acting_therapeutics_and_efficient_drug_delivery_for_cancer_treatment/26015830CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/260158302019-05-01T00:00:00Z |
| spellingShingle | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment Alanod D. AlQahtani (18805930) Biomedical and clinical sciences Medical biotechnology Ophthalmology and optometry Pharmacology and pharmaceutical sciences PEGylations Human serum albumin Targeted cancer cells Drug delivery Half-life extension Protein immunogenicity |
| status_str | publishedVersion |
| title | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment |
| title_full | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment |
| title_fullStr | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment |
| title_full_unstemmed | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment |
| title_short | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment |
| title_sort | Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment |
| topic | Biomedical and clinical sciences Medical biotechnology Ophthalmology and optometry Pharmacology and pharmaceutical sciences PEGylations Human serum albumin Targeted cancer cells Drug delivery Half-life extension Protein immunogenicity |